Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 40 for your search:
Start Over
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15540, NCI-2016-00365, 2014-004824-22, I4T-MC-JVCY, NCT02411448
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8273-CL-0302, NCI-2016-00113, 2015-002894-39, NCT02588261
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pacritinib and Erlotinib Hydrochloride in Treating Patients with Metastatic or Locally Advanced Non-small Cell Lung Cancer after EGFR TKI Treatment
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201503052, NCI-2015-00399, J20001, NCT02342353
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BGBC004, NCI-2015-00730, NCT02424617
Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients with Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9878, NCI-2015-01411, PHI-80, NCT02535338
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Ascorbic Acid, Gemcitabine Hydrochloride, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 11D.365, NCI-2012-00340, 2008-52(1), NCT01555489
Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Stereotactic Radiosurgery and Erlotinib Hydrochloride in Treating Patients with Progressive Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1123, NCI-2013-00976, 11-1695, NCT01573702
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1306, NCI-2013-00737, NCT01822496
Erlotinib Hydrochloride before Surgery in Treating Patients with Stage III Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2013-233, NCI-2013-02219, 2013-233-004, NCT01857271
Cisplatin or Carboplatin and Docetaxel with or without Erlotinib Hydrochloride in Treating Patients with Stage III-IVB Oral Cavity Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0179, NCI-2014-01390, NCT01927744
Maintenance Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Previously Treated Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 092013-070, NCI-2014-02014, NCT02045446
Start Over